Login
$OVID
$2.44 +$0.04 (1.6%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Margaret Alexander Also a director
President, Chief Executive Officer and Director
45 Not stated $1,022,272
Charles Carter
Chief Financial Officer
Title from the Form 8-K dated Jul 6, 2026
Not stated Not stated Not reported
Jeremy M. Levin
Executive Chairman of the Board
72 Not stated $1,934,699
Jeffrey Rona
Chief Business and Financial Officer
57 Since 2021
5 years
$969,164

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 27, 2026 · updated by the 8-K of Jun 3, 2026

Directors
8
serving now
Independent
0 of 2
stated in the proxy; 6 not stated
Average tenure
5.2 years
from year joined
CEO also chairs the board
No
Levin
Director Age On board Independent Committees Other public boards 2025 pay Source
Levin
Not stated Not stated Not independent None stated None stated Not stated
Margaret Alexander
45 2026
this year
Not independent None stated None stated Paid as CEO
Bart Friedman
81 2015
11 years
Not stated
Audit
None stated Not stated
Barbara Duncan
61 2017
9 years
Not stated
Nominating and Corporate Governance
Halozyme Therapeutics, Inc., Atea Pharmaceuticals, Inc., Fusion Pharmaceuticals Inc. $86,266
Stelios Papadopoulos
77 2025
1 year
Not stated
Audit Compensation
Exelixis, Inc. $88,906
Kevin Fitzgerald
58 2021
5 years
Not stated
Nominating and Corporate Governance
None stated $69,940
Karen Bernstein
Not stated Not stated Not stated None stated None stated $89,940
Anna Greka Joined Jun 15, 2026
- - -
Compensation Committee Science and Technology Committee
- -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

3 disclosed in the proxy filed Apr 27, 2026
Jeremy M. Levin, DPhil, MB BChir
99,400

Purchased Common Stock and Warrants in the 2025 private placement (2025 PIPE financing)

RA Capital Healthcare Fund, L.P.
14,999,600

Purchased Common Stock and Warrants in the 2025 private placement (2025 PIPE financing)

Point72 Associates, LLC
24,994,161

Purchased Common Stock and Pre-Funded Warrants in the 2026 private placement (2026 PIPE)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support